Europe — EMA

Paclitaxel Accord

Paclitaxel, the active ingredient in Paclitaxel Accord, is a chemotherapy agent presented as a sterile powder for intravenous infusion use.

Paclitaxel

Request sourcing

Pack/s

What is Paclitaxel?

Paclitaxel, the active ingredient in Paclitaxel Accord, is a chemotherapy agent presented as a sterile powder for intravenous infusion use. It treats a variety of solid tumours and is administered under the supervision of oncologists in hospital settings.

GNH USA supplies Paclitaxel Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

What is Paclitaxel used for?

Paclitaxel is employed across several oncologic indications where microtubule inhibition is beneficial.

- Breast cancer: improves survival outcomes when used in adjuvant or metastatic settings. - Non‑small cell lung cancer: used in combination regimens for advanced disease. - Ovarian cancer: administered as part of first‑line chemotherapy protocols. - Kaposi's sarcoma: provides disease control in HIV‑related cases. - Gastric cancer: used in combination with other agents for metastatic disease.

What are the side effects of Paclitaxel?

Paclitaxel …

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →